Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.

Abstract : The relevance of high-dose chemotherapy followed by auto-SCT in CLL remains to be defined. The aim of the prospective, randomized, GOELAMS LLC 98 trial was to compare two strategies in previously untreated CLL patients aged <60 years. Conventional chemotherapy (Arm A) consisted of six monthly courses of CHOP followed by six CHOP courses in every 3 months in those achieving a complete or PR. Arm A was compared with high-dose therapy with auto-SCT (Arm B), used as consolidation after three CHOP courses in case of CR or very good PR. A total of 86 patients were enrolled, of which 39 and 43 patients were evaluable in arm A and arm B, respectively. The primary endpoint was PFS. On an intent-to-treat basis and with a median follow-up time of 77.1 (range 1-135.5) months, the median PFS was 22 months in Arm A and 53 months in Arm B (P<0.0001). Median survival time was 104.7 months in arm A and 107.4 months in arm B. This trial demonstrates that frontline high-dose therapy with auto-SCT prolongs PFS but does not translate into a survival advantage in advanced CLL patients in the pre-rituximab era.
Type de document :
Article dans une revue
Bone Marrow Transplantation, Nature Publishing Group, 2012, 47 (4), pp.542-8. 〈10.1038/bmt.2011.117〉
Liste complète des métadonnées

http://www.hal.inserm.fr/inserm-00821100
Contributeur : Philippe Saas <>
Soumis le : mardi 7 mai 2013 - 14:34:00
Dernière modification le : jeudi 3 mai 2018 - 15:58:02

Identifiants

Collections

Citation

Annie Brion, Béatrice Mahé, Brigitte Kolb, Bruno Audhuy, Philippe Colombat, et al.. Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial.. Bone Marrow Transplantation, Nature Publishing Group, 2012, 47 (4), pp.542-8. 〈10.1038/bmt.2011.117〉. 〈inserm-00821100〉

Partager

Métriques

Consultations de la notice

142